← All trials
NCT02400957
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2014
- Primary completion
- May 31, 2015
- Completion date
- May 31, 2015
- First posted
- Mar 27, 2015
- Last posted
- Mar 27, 2015
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de San Luis PotosiLead sponsor
- Universidad Autonoma de San Luis PotosiReponsible party - principal investigator
- Universidad Autonoma de San Luis PotosiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.